Dr. Omid Farokhzad, Chair, CEO and Founder of Seer, sits down to discuss how Seer’s cutting edge work with protein and proteomics is removing technological barriers and providing scientists with better tools to make breakthroughs than ever before.
Dr. Farokhzad and host of #ThePlaybook, David Meltzer, chat about a range of topics including the markets that will most benefit from proteomics and why Dr. Farokhzad says their company’s future goal is the diagnosis of disease at the pre-symptomatic level. The pair also share their thoughts on how Seer’s initial public offering in 2020 has impacted the way that the organization is run.
The Playbook With David Meltzer